Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome
- 1 February 2007
- journal article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (2) , 263-264
- https://doi.org/10.1136/bjo.2006.0101477
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Biologic therapies for inflammatory eye diseaseClinical & Experimental Ophthalmology, 2006
- Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational studyClinical Rheumatology, 2006
- Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra)Rheumatology, 2006
- Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 geneActa Paediatrica, 2006
- Blocking IL-1 in systemic inflammationThe Journal of Experimental Medicine, 2005
- Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockadeThe Journal of Experimental Medicine, 2005
- Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndromeRheumatology, 2005
- Anakinra in mutation‐negative NOMID/CINCA syndrome: Comment on the articles by Hawkins et al and Hoffman and PatelArthritis & Rheumatism, 2004
- Response to anakinra in a de novo case of neonatal‐onset multisystem inflammatory diseaseArthritis & Rheumatism, 2004
- Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitorNature, 1990